Nikhil Wagle1,2,3, Rachel A Freedman4,5, Sara M Balch1,2, Ines Vaz-Luis2,6, Tianyu Li7, Nabihah Tayob7, Esha Jain1,2, Karla Helvie2, Jorge E Buendia-Buendia1,8, Erin Shannon1, Steven J Isakoff9,3, Nadine M Tung3,10, Ian E Krop2,3, Nancy U Lin2,3. 1. The Broad Institute of MIT and Harvard, Cambridge, MA, USA. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA. 3. Harvard Medical School, Boston, MA, USA. 4. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA. rafreedman@partners.org. 5. Harvard Medical School, Boston, MA, USA. rafreedman@partners.org. 6. Institut Gustave Roussy, Unit INSERM 981, Villejuif, France. 7. Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. 8. Cellarity, Inc., Cambridge, MA, USA. 9. Massachusetts General Hospital, Boston, MA, USA. 10. Beth Israel Deaconess Medical Center, Boston, MA, USA.
Abstract
PURPOSE: There are limited data on trastuzumab-pertuzumab (HP)-based treatments beyond the first-line, HER2+ metastatic breast cancer (MBC) setting. We conducted a phase II study of eribulin mesylate, which extends survival in MBC, with HP in patients with previously treated HER2+ MBC to evaluate efficacy, toxicity, and genomic alterations driving therapeutic response. METHODS: After a run-in phase for eribulin dosing, two cohorts were enrolled (Cohort A-no prior pertuzumab; Cohort B-prior pertuzumab). All patients received eribulin 1.4 mg/m2 on days 1, 8 with standard-dose HP on day 1 (21-day cycles). The primary endpoint was objective response rate (ORR). Genomic characterization via whole exome sequencing (WES) was completed on tumor DNA and matched germline DNA from 19 patients. RESULTS: The six-patient run-in established a dose of eribulin 1.4 mg/m2 with HP. Cohorts A and B enrolled 17 and 7 patients, respectively. Accrual stopped early due to an evolving treatment landscape and slow enrollment. The ORR was 26.3% (95% Confidence Interval [CI] 9.2-51.2%) in Cohort A and 0% in Cohort B (95% CI 0-41.0%). WES revealed more frequent alterations in TP53 (p < 0.05, q > 0.05) in patients without clinical benefit (disease control for < 24 weeks) which was not significant after multiple hypothesis correction. CONCLUSION: Eribulin-HP had manageable toxicity and modest clinical activity in patients without prior pertuzumab exposure. This study provides a preliminary landscape of somatic alterations in this patient cohort. Our data add to the literature on how genomic alterations may predict for therapy response/resistance, as we work to individualize choices in a quickly evolving HER2+ MBC treatment landscape. TRIAL REGISTRATION: www.clinicaltrials.gov , NCT01912963. Registered 24 July 2013.
PURPOSE: There are limited data on trastuzumab-pertuzumab (HP)-based treatments beyond the first-line, HER2+ metastatic breast cancer (MBC) setting. We conducted a phase II study of eribulin mesylate, which extends survival in MBC, with HP in patients with previously treated HER2+ MBC to evaluate efficacy, toxicity, and genomic alterations driving therapeutic response. METHODS: After a run-in phase for eribulin dosing, two cohorts were enrolled (Cohort A-no prior pertuzumab; Cohort B-prior pertuzumab). All patients received eribulin 1.4 mg/m2 on days 1, 8 with standard-dose HP on day 1 (21-day cycles). The primary endpoint was objective response rate (ORR). Genomic characterization via whole exome sequencing (WES) was completed on tumor DNA and matched germline DNA from 19 patients. RESULTS: The six-patient run-in established a dose of eribulin 1.4 mg/m2 with HP. Cohorts A and B enrolled 17 and 7 patients, respectively. Accrual stopped early due to an evolving treatment landscape and slow enrollment. The ORR was 26.3% (95% Confidence Interval [CI] 9.2-51.2%) in Cohort A and 0% in Cohort B (95% CI 0-41.0%). WES revealed more frequent alterations in TP53 (p < 0.05, q > 0.05) in patients without clinical benefit (disease control for < 24 weeks) which was not significant after multiple hypothesis correction. CONCLUSION: Eribulin-HP had manageable toxicity and modest clinical activity in patients without prior pertuzumab exposure. This study provides a preliminary landscape of somatic alterations in this patient cohort. Our data add to the literature on how genomic alterations may predict for therapy response/resistance, as we work to individualize choices in a quickly evolving HER2+ MBC treatment landscape. TRIAL REGISTRATION: www.clinicaltrials.gov , NCT01912963. Registered 24 July 2013.
Authors: José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron Journal: N Engl J Med Date: 2006-12-28 Impact factor: 91.245
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni Journal: Nat Rev Clin Oncol Date: 2011-11-29 Impact factor: 66.675
Authors: Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés Journal: N Engl J Med Date: 2015-02-19 Impact factor: 91.245
Authors: Linda T Vahdat; Brian Pruitt; Carol J Fabian; Ragene R Rivera; David A Smith; Elizabeth Tan-Chiu; Jonathan Wright; Antoinette R Tan; Noshir A Dacosta; Ellen Chuang; John Smith; Joyce O'Shaughnessy; Dale E Shuster; Nicole L Meneses; Kumari Chandrawansa; Fang Fang; Patricia E Cole; Simon Ashworth; Joanne L Blum Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: Rachel A Freedman; Rebecca S Gelman; Jeffrey S Wefel; Michelle E Melisko; Kenneth R Hess; Roisin M Connolly; Catherine H Van Poznak; Polly A Niravath; Shannon L Puhalla; Nuhad Ibrahim; Kimberly L Blackwell; Beverly Moy; Christina Herold; Minetta C Liu; Alarice Lowe; Nathalie Y R Agar; Nicole Ryabin; Sarah Farooq; Elizabeth Lawler; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Rachel A Freedman; Rebecca S Gelman; Carey K Anders; Michelle E Melisko; Heather A Parsons; Anne M Cropp; Kelly Silvestri; Christine M Cotter; Kathryn P Componeschi; Juan M Marte; Roisin M Connolly; Beverly Moy; Catherine H Van Poznak; Kimberly L Blackwell; Shannon L Puhalla; Rachel C Jankowitz; Karen L Smith; Nuhad Ibrahim; Timothy J Moynihan; Ciara C O'Sullivan; Julie Nangia; Polly Niravath; Nadine Tung; Paula R Pohlmann; Robyn Burns; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin Journal: J Clin Oncol Date: 2019-03-12 Impact factor: 44.544